A monoclonal antibody against human neurofilament light chain 21D2-30D3, its products and applications
By developing the anti-human neurofilament light chain monoclonal antibody 21D2-30D3, the problems of insufficient specificity and detection range in the existing technology have been solved, achieving high specificity and high affinity binding to human NFL, thus improving the sensitivity and specificity of detection.
Patent Information
- Application Number
- CN202310309954.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-27
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-03-27
AI Technical Summary
Existing anti-human neurofilament light chain monoclonal antibodies are insufficient in terms of specificity and detection range, making it difficult to meet the requirements of high sensitivity and high specificity.
A monoclonal antibody 21D2-30D3 against the human neurofilament light chain was developed. Its light chain belongs to kappa and its heavy chain belongs to IgG1. The amino acid and nucleotide sequences have high homology. A high-purity monoclonal antibody was obtained through preparation and purification processes and used to prepare products for detecting human NFL levels.
It achieves high specificity and high affinity binding to human NFL, enabling early detection and treatment of related diseases, and improving the specificity and scope of detection.
Smart Images

Figure CN116355091B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of cell biotechnology and immunology, specifically relating to a monoclonal antibody (21D2-30D3) against human neurofilament light chains, its products, and applications. Background Technology
[0002] Neurofibrils, as members of the intermediate filament protein family, are major cytoskeletal structural proteins in neurons, composed of four distinct subunits. Among these, the neurofilament light polypeptide (NFL), neurofilament medium chain (NFM), and neurofilament heavy chain (NFH) subunits belong to type IV intermediate filament proteins, present in various nervous systems and highly expressed in neurons. Studies have shown that NFL is closely related to the progression or recurrence of various neurological diseases, serving as an important biomarker for predicting disease progression or assessing treatment response. Therefore, highly sensitive and specific methods for detecting NFL are of great significance for the early detection, early treatment, and improved prognosis of related diseases.
[0003] While numerous reports exist on anti-NFL monoclonal antibodies, their detection specificity, pairing ability, and detection range vary significantly. Therefore, the development of highly specific, high-affinity anti-NFL antibodies and antibody pairs is crucial for the development of NFL immunoassay reagents and kits. Summary of the Invention
[0004] In order to overcome the shortcomings of the prior art, the present invention aims to provide a monoclonal antibody 21D2-30D3 against human neurofilament light chains, its products and applications, so as to solve the problems of low specificity and small detection range of existing anti-NFL monoclonal antibodies.
[0005] To achieve the above objectives, the present invention employs the following technical solution:
[0006] A first aspect of the present invention provides a monoclonal antibody 21D2-30D3 against human neurofilament light chains, the monoclonal antibody 21D2-30D3 comprising a light chain and a heavy chain, wherein the light chain belongs to kappa and the heavy chain belongs to IgG1; wherein the amino acid sequences of the three complementarity-determining regions (LCDR1-3) of the variable region of the light chain of the monoclonal antibody 21D2-30D3 are shown in SEQ ID No. 1-3, respectively, and the amino acid sequences of HCDR1-3 of the variable region of the heavy chain are shown in SEQ ID No. 10-12, respectively.
[0007] Furthermore, the light chain variable region (LFR1-4) of the monoclonal antibody 21D2-30D3 has at least 90% sequence identity with the amino acid sequences shown in SEQ ID No. 4-7, and the heavy chain variable region (HFR1-4) has at least 90% sequence identity with the amino acid sequences shown in SEQ ID No. 13-16.
[0008] Furthermore, the light chain variable region of the monoclonal antibody 21D2-30D3 has a VL with at least 90% sequence identity, preferably 95% sequence identity, of the amino acid sequence shown in SEQ ID No. 8, and the heavy chain variable region has a VH with at least 90% sequence identity, preferably 95% sequence identity, of the amino acid sequence shown in SEQ ID No. 17.
[0009] Furthermore, the light chain variable region of the monoclonal antibody 21D2-30D3 has a VL region that is at least 90% sequence identical to the nucleotide sequence shown in SEQ ID No. 9, preferably 95% sequence identical, and the heavy chain variable region has a VH region that is at least 90% sequence identical to the nucleotide sequence shown in SEQ ID No. 18, preferably 95% sequence identical.
[0010] 1) A second aspect of the present invention provides a product for detecting human NFL levels, comprising the monoclonal antibody or a functional fragment thereof described in the first aspect, or a nucleic acid molecule, recombinant expression vector, or host cell encoding the monoclonal antibody or a functional fragment thereof described in the first aspect of the present invention; wherein:
[0011] a) Nucleic acid molecule: The nucleic acid molecule encodes the monoclonal antibody or its functional fragment as described in the first aspect of the present invention;
[0012] b) Recombinant expression vector: the recombinant expression vector comprises the nucleic acid molecule described in a);
[0013] c) Host cell: The host cell contains the recombinant expression vector described in b);
[0014] Furthermore, the recombinant expression vector has a signal peptide operatively linked to an antibody;
[0015] Furthermore, the recombinant expression vector further includes transcriptional regulatory elements.
[0016] Furthermore, the product also includes reagents for performing antigen-antibody reactions or reagents for detecting reactions;
[0017] Furthermore, reagents used to perform antigen-antibody reactions include buffers, salts, diluents, etc.
[0018] The third aspect of the present invention provides a method according to any one of the following:
[0019] 1) A method for preparing the monoclonal antibody according to the first aspect of the present invention, the method comprising: culturing the host cell according to the second aspect of the present invention, optionally isolating the monoclonal antibody from the host cell and / or the culture medium in which the host cell is grown;
[0020] 2) A method for detecting NFL protein in a sample, the method comprising contacting the sample to be tested with the monoclonal antibody as described in the first aspect of the present invention to determine the level of NFL in the sample to be tested.
[0021] Furthermore, the method described in 1) also includes purifying the monoclonal antibody;
[0022] Furthermore, the host cell is selected from mammalian cells;
[0023] Furthermore, the cells are selected from 293T cells, CHO cells, or Expi293F cells. TM cell;
[0024] The fourth aspect of the invention provides for any of the following applications:
[0025] 1) The application of the monoclonal antibody described in the first aspect of the present invention and the product described in the second aspect of the present invention in the detection of NFL;
[0026] 2) The application of the monoclonal antibody described in the first aspect of the present invention and the product described in the second aspect of the present invention in the preparation of products for detecting NFL levels;
[0027] 3) The use of the monoclonal antibody described in the first aspect of the present invention and the product described in the second aspect of the present invention in the preparation of products for diagnosing diseases related to NFL levels;
[0028] Furthermore, the product includes a reagent kit.
[0029] Furthermore, the kit includes: a colloidal gold immunoassay kit, a chemiluminescence immunoassay kit, a radioimmunoassay kit, an enzyme-linked immunosorbent assay kit, a fluorescence immunoassay kit, and a microfluidic chip.
[0030] Compared with the prior art, the present invention has the following beneficial effects:
[0031] This invention discloses a monoclonal antibody 21D2-30D3, and explicitly provides the amino acid sequences of its light and heavy chain variable regions (LCDRs). The light chain belongs to kappa, and the heavy chain belongs to IgG1. The amino acid sequences of the three LCDRs (LCDR1-3) of the light chain variable region are shown in SEQ ID No. 1-3, and the amino acid sequences of the HCDR1-3 of the heavy chain variable region are shown in SEQ ID No. 10-13. The amino acid sequences of the four frame regions (LFR1-4) of the light chain variable region and the four frame regions (HFR1-4) of the heavy chain variable region are also disclosed. Experiments have demonstrated that the monoclonal antibody of this invention exhibits good binding activity and high specificity with human NFL, and can be used for the detection of NFL. Attached Figure Description
[0032] Figure 1 These are the results of antibody titer assays in mice immunized with human NFL.
[0033] Figure 2 These are the electrophoresis results of monoclonal antibodies from 21D2 to 30D3; M, Marker; 1, ascites fluid before purification; 2, after purification;
[0034] Figure 3 These are the results of the monoclonal antibody 21D2-30D3 subtype identification;
[0035] Figure 4 This is the result of ELISA verification of the specificity of the monoclonal antibody 21D2-30D3;
[0036] Figure 5 This is the result of Western blot verification of the specificity of the monoclonal antibody 21D2-30D3; M, Marker; 1, HeLa cells (as negative control); 2, PC12 cells (highly differentiated); 3, PC12 cells (lowly differentiated); 4, SHSY5Y cells; 5, HEK293A cells; 6, HEK293NT cells;
[0037] Figure 6 The results are from the immunofluorescence assay using the monoclonal antibody 21D2-30D3. Detailed Implementation
[0038] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.
[0039] It should be noted that the terms "comprising" and "having" and any variations thereof in the specification and claims of this invention are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or units is not necessarily limited to those steps or units that are explicitly listed, but may include other steps or units that are not explicitly listed or that are inherent to such processes, methods, products, or devices.
[0040] The present invention will now be described in further detail with reference to the accompanying drawings:
[0041] 1. Preparation of NFL protein
[0042] The NFL gene sequence was synthesized into the PUC vector, and then the target gene was cloned into the pET-32a vector. The plasmid was extracted, identified by double enzyme digestion, and sequenced for alignment. The constructed prokaryotic expression plasmid was transformed into *E. coli* BL21(DE3) competent cells. Single colonies were picked and inoculated into LB medium, incubated at 37°C until the OD value reached 0.5–1, and then IPTG was added and incubated overnight at 16°C to induce expression. The bacterial cells were collected, sonicated, centrifuged, and the supernatant was collected. The protein purified by Ni column affinity chromatography was dialyzed and concentrated to obtain a high concentration of NFL protein.
[0043] 2. Obtaining hybridoma cells
[0044] Step 1: Immunize mice with NFL
[0045] Two female Balb / c mice aged 5-8 weeks were used. After one week of acclimatization, 50 μg of N protein was mixed with Freund's complete adjuvant at a 1:1 ratio, emulsified, and injected subcutaneously at four points to complete the first immunization. Three weeks later, 50 μg of N protein was mixed with Freund's incomplete adjuvant at a 1:1 ratio, emulsified, and injected subcutaneously at four points to complete the second immunization. Three weeks later, 50 μg of N protein was mixed with an appropriate amount of physiological saline and injected intraperitoneally to complete the third immunization.
[0046] Step 2: ELISA detection of antibody production in immunized mice
[0047] Three weeks after the third immunization, tail blood was collected from mice to collect serum, and antibody production in immunized mice was detected by ELISA. The specific steps were as follows: NFL was coated on the ELISA plate, 100 ng / well, and incubated overnight at 4°C; PBST was used to wash the plates three times, 2 min each time, and the plates were patted dry; 3% BSA was used to block the plates at 37°C for 2 h; PBST was used to wash the plates three times, 2 min each time, and the plates were patted dry; mouse serum diluted in a certain ratio was added, 100 μL / well, and the plates were incubated at 37°C for 1 h; PBST was used to wash the plates three times, 2 min each time, and the plates were patted dry; goat anti-mouse IgG-HRP was added, 100 μL / well, and the plates were incubated at 37°C for 40 min; PBST was used to wash the plates three times, 2 min each time, and the plates were patted dry; chromogenic solution was added, 100 μL / well, and the plates were incubated at room temperature (RT) for 10 min, then the incubation was stopped with stop solution, and the absorbance was measured on a microplate reader. The measurement wavelength was 450 nm, and the reference wavelength was 630 nm. Figure 1 The antibody titer test results of one immunized mouse used in subsequent experiments are presented. The results show that, compared to unimmunized normal mice, the antibody titer of the immunized mouse coated with the target antigen NFL was higher than 1:320,000; however, the immunized mouse did not respond when coated with the unrelated antigen BSA. This result indicates that the immunized mouse produced a specific immune response to the immunogen NFL and can be used for subsequent experiments.
[0048] Step 3: Cell Fusion
[0049] SP2 / 0 myeloma cells were acclimated to 20% fetal bovine serum for one week. Three days prior to fusion, 50 μg of NFL was mixed with an appropriate amount of physiological saline and injected intraperitoneally as a booster immunization. On the day of fusion, the mice were sacrificed, and the spleens were aseptically harvested, ground, and washed twice with serum-free medium. Spleen cells were mixed with SP2 / 0 cells at a ratio of 10:1, centrifuged at 1200 rpm for 10 min, and the supernatant was discarded. The bottom of the centrifuge tube was gently tapped to loosen the cell pellet. 1 mL of 45% PEG solution preheated to 37°C was slowly added over 30 seconds. After standing at room temperature for 90 seconds, incomplete medium preheated to 37°C was slowly added. After mixing, the mixture was centrifuged at 800 rpm for 10 min, and the supernatant was discarded. 40 mL of complete medium preheated to 37°C was added, mixed, and then transferred to a 96-well cell culture plate inoculated with peritoneal macrophages. The plate was incubated at 37°C in a 5% CO2 incubator. HAT and HT were added every other day from day 2 to 7 after fusion for screening of fused cells.
[0050] Step 4: ELISA detection of positive hybridoma cells and cloning of hybridoma cells
[0051] 7-10 days after fusion, observe the growth of hybridoma cells. When the cells in the wells exceed 1 / 3 of the bottom, detect the secretion of hybridoma antibodies. The detection steps are as follows: ELISA plate, NFL 100ng / well, incubate overnight at 4℃; wash 3 times with PBST, 2 min / time, and pat dry; block with 3% BSA at 37℃ for 2 h; wash 3 times with PBST, 2 min / time, and pat dry; add hybridoma cell supernatant, 100 μL / well, incubate at 37℃ for 1 h; wash 3 times with PBST, 2 min / time, and pat dry; add goat anti-mouse IgG-HRP, 100 μL / well, incubate at 37℃ for 40 min; wash 3 times with PBST, 2 min / time, and pat dry; add chromogenic solution, 100 μL / well, incubate at RT for 10 min, then stop with stop solution. Measure the absorbance on a microplate reader. The measurement wavelength is 450 nm, and the reference wavelength is 630 nm. Clones with high OD values were selected for subcloning, and ELISA screening was performed again after 7-10 days. After three rounds of cloning, one positive clone was finally selected and named 21D2-30D3.
[0052] 3. Preparation of monoclonal antibodies from ascites fluid (21D2-30D3)
[0053] 500 μL of ascites adjuvant was injected into the peritoneal cavity of 10-week-old Balb / c mice. Seven days later, hybridoma cells were cultured to the logarithmic growth phase, and the cell density was adjusted to 2 × 10⁻⁶. 6 Ascites fluid was collected 7-10 days later, with a volume of 1 / mL and an intraperitoneal injection of 500 μL.
[0054] 4. Purification of monoclonal antibody 21D2-30D3
[0055] Binding: Ascites fluid was diluted with binding / wash buffer (pH 7.0), centrifuged, and the supernatant was collected. Protein A beads were added, mixed well, and incubated overnight at 4°C on a shaker. Equilibration: The column was equilibrated twice with binding / wash buffer. Loading: The overnight binding buffer was added to the column. Washing: After the protein A beads settled to the bottom of the column, the column was washed twice with binding / wash buffer. Elution: The antibody bound to protein A was eluted with elution buffer (pH 3.0), and immediately 1 / 10 volume of neutralizing buffer (pH 8.5) was added to the eluent and mixed well. Ultrafiltration: The elution and neutralization buffer obtained in the previous step was concentrated using an ultrafiltration tube, and the liquid was gradually replaced with antibody storage solution PBS (pH 7.2). After determining the concentration of purified 21D2-30D3 using the BCA method, an appropriate amount was taken and subjected to SDS-PAGE electrophoresis and Coomassie brilliant blue staining simultaneously with the original ascites fluid. The results are as follows. Figure 2As shown, the heavy and light chain bands of the antibody can be clearly seen, and the amount of impurities in the ascites fluid is significantly reduced after purification, indicating a significant improvement in antibody purity.
[0056] 5. Monoclonal antibody subtype identification
[0057] ELISA plates were incubated overnight at 4°C with 100 ng NFL per well. The plates were washed three times with PBST (2 min each time) and patted dry. Blocking was performed with 3% BSA at 37°C for 2 h. The plates were then washed three times with PBST (2 min each time) and patted dry. Hybridoma cell supernatant was added at 100 μL per well and incubated at 37°C for 1 h. The plates were washed three times with PBST (2 min each time) and patted dry. HRP-labeled rabbit anti-mouse secondary antibody (IgG1, IgG2a, IgG2b, IgG3, IgM, kappa) was added at 100 μL per well and incubated at 37°C for 40 min. The plates were washed three times with PBST (2 min each time) and patted dry. chromogenic buffer was added at 100 μL per well, and incubation was performed at RT for 10 min. The incubation was terminated with stop solution. The absorbance was measured using a microplate reader at 450 nm and a reference wavelength of 630 nm. The experimental results are as follows: Figure 3 As shown, the OD values of 21D2-30D3 IgG1 and kappa types are significantly higher than those of other subtypes and the negative control. Therefore, the heavy chain of the 21D2-30D3 monoclonal antibody is of the IgG1 type, and the light chain is of the kappa type.
[0058] 6. ELISA verification of the specificity of monoclonal antibody 21D2-30D3
[0059] The purified NFL expressed in Example 1, the laboratory-existing NFL C-terminal truncated variant (NFL-C), and His-SARS-N protein were diluted to 1 μg / mL with coating buffer and used for coating ELISA plates (100 ng / well, incubated overnight at 4°C); washed three times with PBST for 2 min each time, and patted dry; 3% BSA was then added. Block at 37℃ for 2 h; wash 3 times with PBST, 2 min each time, and pat dry; add 100 μL / well of hybridoma cell 21D2-30D3 supernatant, and incubate at 37℃ for 1 h; wash 3 times with PBST, 2 min each time, and pat dry; add 100 μL / well of goat anti-mouse IgG-HRP, and incubate at 37℃ for 40 min; wash 3 times with PBST, 2 min each time, and pat dry; add 100 μL / well of chromogenic solution, incubate at RT for 10 min, and then stop the incubation with stop solution. Measure the absorbance on a microplate reader. The measurement wavelength is 450 nm, and the reference wavelength is 630 nm. Experimental results (Table 1 and...) Figure 4 Note: Monoclonal antibodies 21D2-30D3 can specifically recognize NFL.
[0060] Table 1. ELISA validation of the specificity of monoclonal antibody 21D2-30D3
[0061]
[0062] 7. Western blot validation of the specificity of monoclonal antibody 21D2-30D3
[0063] Total protein was collected from HeLa, PC12 (highly differentiated), PC12 (lowly differentiated), SHSY5Y, HEK293, and HEK293NT cells, respectively. After quantification using the BCA method, 20 μg was subjected to SDS-PAGE, followed by transfer to a PVDF membrane. The membrane was blocked with 5% skim milk powder and incubated with purified 21D2-30D3 cells. After washing three times with TBST, the cells were incubated with goat anti-mouse IgG-HRP. After washing three times with TBST, ECL staining was performed. Results ( Figure 5 The results showed that at the 68 kDa band, NFL-specific bands appeared in positive cell PC12 (highly differentiated), PC12 (lowly differentiated), SHSY5Y, HEK293, and HEK293NT protein samples, while no obvious bands appeared in negative HeLa cells. This result indicates that 21D2-30D3 can specifically recognize NFL protein.
[0064] 8. Application of monoclonal antibody 21D2-30D3 in immunofluorescence detection
[0065] HeLa and SHSY5Y cells were seeded onto slides, fixed with paraformaldehyde, washed three times with PBST, and incubated at RT for 21 days to 30 days. After washing with PBST, the slides were incubated at RT for 30 minutes with Alexa Fluor 549-labeled goat anti-mouse IgG antibody. After washing with PBST, the slides were mounted with mounting medium containing DAPI. The staining results were observed under a fluorescence microscope. Experimental results ( Figure 6 The results showed that the cell nuclei of both groups of cells were significantly stained. Figure 6 DAPI was used, but after incubation with the monoclonal antibody 21D2-30D3, no obvious green fluorescence was observed in the negative HeLa cells, indicating that these cells do not express NFL, while the positive SHSY5Y cells showed obvious green fluorescence, i.e., NFL staining (DAPI). Figure 6 The green fluorescence of NFL in SHSY5Y cells can be well superimposed with the blue fluorescence of the cell nucleus, further demonstrating that the monoclonal antibody 21D2-30D3 can specifically bind to NFL.
[0066] 9. Monoclonal antibody 21D2-30D3 sequence determination
[0067] Total RNA was extracted from hybridoma cells and cDNA was obtained by reverse transcription. The variable regions of the antibody heavy and light chains were amplified using the 5'RACE method. The amplified fragments were subcloned into the pEASY-Blunt vector, and the plasmid was extracted and sequenced. The antibody light and heavy chain sequences (SEQ ID No. 8-9 and 17-18) were obtained, and the CDR region of the antibody amino acid sequence was labeled using the Kabat method.
[0068] In summary, the monoclonal antibody 21D2-30D3 provided in this invention has good binding activity with human NFL protein and high specificity, and can be used for the detection of NFL.
[0069] The above content is only for illustrating the technical concept of the present invention and should not be construed as limiting the scope of protection of the present invention. Any modifications made to the technical solution based on the technical concept proposed in this invention shall fall within the scope of protection of the claims of this invention.
Claims
1. A monoclonal antibody against human neurofilament light chain, characterized in that, It includes a light chain and a heavy chain, wherein the light chain belongs to kappa and the heavy chain belongs to IgG1; wherein: The amino acid sequences of the three complementarity-determining regions LCDR1, LCDR2, and LCDR3 of the light chain variable region are shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively. The amino acid sequences of the three complementarity-determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region are shown in SEQ ID No. 10, SEQ ID No. 11 and SEQ ID No. 12, respectively.
2. The monoclonal antibody against human neurofilament light chains according to claim 1, characterized in that, The amino acid sequences of the light chain variable region framework regions LFR1, LFR2, LFR3, and LFR4 of this monoclonal antibody against human neurofilament light chains are shown in SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, and SEQ ID No. 7, respectively. The amino acid sequences of the heavy chain variable region framework regions HFR1, HFR2, HFR3 and HFR4 of this monoclonal antibody against the human neurofilament light chain are shown in SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15 and SEQ ID No. 16, respectively.
3. The monoclonal antibody against human neurofilament light chains according to claim 1, characterized in that, The light chain variable region of the monoclonal antibody against human neurofilament light chain has at least 90% sequence identity with the amino acid sequence shown in SEQ ID No. 8; the heavy chain variable region of the monoclonal antibody against human neurofilament light chain has at least 90% sequence identity with the amino acid sequence shown in SEQ ID No.
17.
4. The monoclonal antibody against human neurofilament light chains according to claim 3, characterized in that, The light chain variable region of this monoclonal antibody against human neurofilament light chain has 95% sequence identity with the amino acid sequence shown in SEQ ID No. 8; the heavy chain variable region of this monoclonal antibody against human neurofilament light chain has 95% sequence identity with the amino acid sequence shown in SEQ ID No.
17.
5. The monoclonal antibody against human neurofilament light chains according to claim 1 or 2, characterized in that, The light chain variable region of the monoclonal antibody against human neurofilament light chain has at least 90% sequence identity with the nucleotide sequence shown in SEQ ID No. 9; the heavy chain variable region of the monoclonal antibody against human neurofilament light chain has at least 90% sequence identity with the nucleotide sequence shown in SEQ ID No.
18.
6. The monoclonal antibody against human neurofilament light chains according to claim 5, characterized in that, The light chain variable region of this monoclonal antibody against human neurofilament light chain has 95% sequence identity with the nucleotide sequence shown in SEQ ID No. 9; the heavy chain variable region of this monoclonal antibody against human neurofilament light chain has 95% sequence identity with the nucleotide sequence shown in SEQ ID No.
18.
7. A product for detecting NFL levels in humans, characterized in that, include: a) A nucleic acid molecule encoding a monoclonal antibody against human neurofilament light chain as described in any one of claims 1 to 6; b) A recombinant expression vector comprising the nucleic acid molecule described in a); c) A host cell containing the recombinant expression vector described in b).
8. The use of the monoclonal antibody against human neurofilament light chains according to any one of claims 1 to 6 and / or the product for detecting human NFL levels according to claim 7 in the preparation of a product for detecting NFL, characterized in that, The products include testing reagents, kits, or test strips.
Citation Information
Patent Citations
Monoclonal antibody against human neurofilament light polypeptide (NEFL) and application thereof
CN110616192A
Antibodies to Plasminogen Activator inhibitor-1 (PAI-1) and uses thereof
CN112142845A
